PCVX Share Price Performance
US$55.94
-17.88 (-24.22%)
48.7% undervalued intrinsic discount
US$109.00
Fair Value
Price US$55.94
AnalystConsensusTarget US$109.00
AnalystLowTarget US$67.00
AnalystHighTarget US$163.00
Fair ValueUS$109.00
Share Pricen/a
Vaxcyte, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
PCVX Community Narratives
AN
Fair Value US$109 48.7% undervalued intrinsic discount
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$67 16.5% undervalued intrinsic discount
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$163 65.7% undervalued intrinsic discount
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use. What are the underlying business or industry changes driving this perspective?Read more
6
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$109
48.7% undervalued intrinsic discount
Fair Value
Profit Margin
12.51%
Future PE
840.43x
Price in 2029
US$0
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
Catalysts About Vaxcyte Vaxcyte is a vaccine company focused on pneumococcal conjugate vaccines and a Group A Strep program, using a carrier sparing platform to target broad disease coverage. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$163
65.7% undervalued intrinsic discount
Fair Value
Profit Margin
10.89%
Future PE
764.43x
Price in 2029
US$0
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
Catalysts About Vaxcyte Vaxcyte is a vaccine company developing pneumococcal conjugate vaccines and a Group A Strep candidate using a carrier sparing platform and large scale manufacturing infrastructure. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$67
16.5% undervalued intrinsic discount
Fair Value
Profit Margin
10.9%
Future PE
8.71kx
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Future Late Stage Vaccine Programs And Manufacturing Capacity Will Drive Long Term Opportunity
Fair Value: US$109 48.7% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Vaccine Programs And New Manufacturing Capacity Will Underpin Long Term Upside
Fair Value: US$163 65.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Late Stage Vaccine Trials And Manufacturing Buildout Will Shape Balanced Long Term Outlook
Fair Value: US$67 16.5% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vaxcyte, Inc. Key Details
About PCVX
- Founded
- 2013
- Employees
- 507
- CEO
- WebsiteView website
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
